Epioxa Cross-linking Kit
NDC Package 25357-024-01
Package Information
Epioxa Cross-linking (riboflavin 5-phosphate ophthalmic) kits is ePIOXA HD and EPIOXA are indicated in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O2n System and the Boost Goggles. This formulation utilizes a kit delivery system. Marketed by Glaukos Corporation, this product is identified by NDC 25357-024 and is authorized under FDA application NDA219910.
Identification & Billing
- RxCUI: 2727363 - riboflavin 5'-phosphate 0.177 % Ophthalmic Solution
- RxCUI: 2727363 - riboflavin 5'-phosphate 1.77 MG/ML Ophthalmic Solution
- RxCUI: 2727363 - riboflavin 5'-phosphate (as riboflavin 5'-phosphate sodium) 0.177 % Ophthalmic Solution
- RxCUI: 2727368 - Epioxa 0.177 % Ophthalmic Solution
- RxCUI: 2727368 - riboflavin 5'-phosphate 1.77 MG/ML Ophthalmic Solution [Epioxa]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 25357 - Glaukos Corporation
- 25357-024 - Epioxa Cross-linking
- 25357-024-01 - 1 KIT in 1 CARTON * 1 SYRINGE, GLASS in 1 POUCH (25357-026-01) / 2 mL in 1 SYRINGE, GLASS * 1 SYRINGE, GLASS in 1 POUCH (25357-027-01) / 2 mL in 1 SYRINGE, GLASS
- 25357-024 - Epioxa Cross-linking
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 25357-024-01 identifies a specific commercial package of 1 kit in 1 carton * 1 syringe, glass in 1 pouch (25357-026-01) / 2 ml in 1 syringe, glass * 1 syringe, glass in 1 pouch (25357-027-01) / 2 ml in 1 syringe, glass of Epioxa Cross-linking, a human prescription drug labeled by Glaukos Corporation. This kit is formulated for ophthalmic use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Glaukos Corporation on January 16, 2026. The current certification is valid through December 31, 2026.
How is this Glaukos Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 25357002401. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
